
Just twelve weeks after its strategic realignment, the Innsbruck-based startup femble has achieved another significant milestone: Dr. Raoul Scherwitzl, Co-Founder and Co-CEO of the successful Femtech company Natural Cycles, has joined as a new angel investor.
Originally launched as an app-based health platform for menstrual health issues with an engaged community of over 40,000 women, femble has recently adjusted its business model.
The company now focuses on strengthening the doctor-patient relationship through a digital platform. This strategic shift was driven by extensive market feedback and the needs of medical professionals.
Dr Raoul Scherwitzl brings valuable expertise and a strong network to the partnership, drawing from his experience with Natural Cycles.
His investment underscores confidence in femble’s new direction and the company’s potential to significantly improve information exchange and relationships between doctors and patients.
Raoul Scherwitzl said: “The problem statement convinced me—through my experience in digital health solutions, I know this is a real pain point.
“femble addresses a fundamental need and has the potential to sustainably enhance the interaction between doctors and patients.”
femble Co-Founder Daniel Steiner added: “Raoul’s support is a major milestone for femble. His expertise in the Femtech sector and his commitment to innovative health solutions will help us drive our vision forward.”
Since its founding in 2021, Daniel Steiner and Lina Graf have continuously worked to make medical knowledge more accessible.
With the development of a specialized software solution for doctors and plans for international expansion—including a move into New York—femble is setting new standards in the digital health industry.
femble Co-Founder, Lina Graf, added: “We are thrilled about Raoul’s investment. It validates our approach and motivates us to continue fundamentally strengthening the doctor-patient relationship with femble.”
Newsletter
Sign up for free weekly updates
The latest femtech news, research and investment, straight to your inbox.









